Published in Medical Letter on the CDC and FDA, November 23rd, 2008
Daniel O. Wilds, SCOLR Pharma's President and CEO, said, "We had a very productive third quarter making significant progress advancing our lead product candidates and securing additional non-dilutive operating capital while maintaining financial discipline. Most importantly, yesterday we reported favorable top-line results from our pivotal Phase III trial to evaluate the safety and efficacy of our 12 hour CDT(R) 600 mg extended-release (ER) ibuprofen...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA